Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBTG Share News (BTG)

  • There is currently no data for BTG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BTG Says First Patient Treated With TheraSphere In Singapore

Thu, 11th Jun 2015 06:39

LONDON (Alliance News) - Specialist healthcare company BTG PLC said Thursday that the first patient in Sinapore has been treated with TheraSphere, a treatment for primary liver cancer and metastatic colorectal cancer.

"Today's announcement is an important milestone for this therapy and for BTG's geographic expansion in Asia. Singapore is the second Asian market where we have launched TheraSphere and we're proud to be providing a new treatment option for patients with liver cancer," said General Manager of BTG Asia James Glasgow in a statement.

In Singapore, TheraSphere is approved for primary liver cancer and liver cancer that has spread from another point of origin.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
15 Jul 2015 05:18

AGM, EGM Calendar - Week Ahead

Read more
14 Jul 2015 14:59

AGM, EGM Calendar - Week Ahead

Read more
14 Jul 2015 05:18

AGM, EGM Calendar - Week Ahead

Read more
13 Jul 2015 15:07

AGM, EGM Calendar - Week Ahead

Read more
13 Jul 2015 05:17

AGM, EGM Calendar - Week Ahead

Read more
10 Jul 2015 16:11

AGM, EGM Calendar - Week Ahead

Read more
10 Jul 2015 05:17

AGM, EGM Calendar - Week Ahead

Read more
9 Jul 2015 15:21

AGM, EGM Calendar - Week Ahead

Read more
9 Jul 2015 05:23

AGM, EGM Calendar - Week Ahead

Read more
8 Jul 2015 15:20

AGM, EGM Calendar - Week Ahead

Read more
29 Jun 2015 14:51

Investec affirms 'buy' rating for BTG, confident about varicose vein treatment

Investec reiterated a 'buy' rating and price target of 647p for pharmaceuticals firm BTG after reappraising its key product Varithena. The bank said investors overreacted to concerns over BTG's earning profile, in particular the varicose vein treatment Varithena. "After interviewing physicians and

Read more
11 Jun 2015 10:26

WINNERS & LOSERS: RBS Rises, Royal Mail Sinks On UK Government Moves

Read more
11 Jun 2015 08:35

BROKER RATINGS SUMMARY: Liberum Raises Majestic Wine To Buy From Hold

Read more
27 May 2015 08:34

BROKER RATINGS SUMMARY: Brewin Dolphin Cut To Hold By Peel Hunt, Numis

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.